A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Sponsors ArQule
- 16 Oct 2017 According to an ArQule media release, company anticipates to complete enrollment of patients needed to perform the interim analysis through the first part of 2019.
- 19 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.
- 24 Jul 2017 Status changed from planning to recruiting.